Hans Peter Schwarz
Overview
Explore the profile of Hans Peter Schwarz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
787
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jampol L, Tauscher R, Schwarz H
JAMA Ophthalmol
. 2021 Sep;
139(10):1135-1136.
PMID: 34473193
No abstract available.
2.
Weber A, Engelmaier A, Mohr G, Haindl S, Schwarz H, Turecek P
J Pharm Biomed Anal
. 2016 Nov;
132:207-214.
PMID: 27764736
BAX 855 (ADYNOVATE) is a PEGylated recombinant factor VIII (rFVIII) that showed prolonged circulatory half-life compared to unmodified rFVIII in hemophilic patients. Here, the development and validation of a novel...
3.
Weber A, Engelmaier A, Hainzelmayer S, Minibeck E, Anderle H, Schwarz H, et al.
Bioconjug Chem
. 2015 Sep;
26(10):2133-42.
PMID: 26334218
BAX 855 is a PEGylated recombinant factor VIII preparation that showed prolonged circulatory half-life in nonclinical and clinical studies. This paper describes the development, validation, and application of a novel...
4.
Bechtold S, Beyerlein A, Bonfig W, Dalla Pozza R, Putzker S, Otto R, et al.
Horm Res Paediatr
. 2014 Aug;
82(3):171-8.
PMID: 25171196
Background/aims: Glucocorticoid treatment may influence bone and muscle development in patients with congenital adrenal hyperplasia (CAH). This study evaluated bone mineral density (BMD), bone geometry and muscle mass. Methods: 73...
5.
Bonfig W, Schwarz H
Clin Endocrinol (Oxf)
. 2014 May;
81(6):871-5.
PMID: 24818525
Introduction: Infants with congenital adrenal hyperplasia (CAH) require higher doses of fludrocortisone (FC) due to physiological mineralocorticoid resistance. The adequacy of mineralocorticoid replacement should be closely monitored to avoid hypertension....
6.
Dietrich B, Schiviz A, Hoellriegl W, Horling F, Benamara K, Rottensteiner H, et al.
Int J Hematol
. 2013 Sep;
98(5):525-32.
PMID: 24061775
Baxter has developed a new recombinant factor IX (rFIX) drug product (BAX326) for treating patients with hemophilia B, or congenital FIX deficiency. An extensive preclinical program evaluated the pharmacokinetics, efficacy,...
7.
Whelan S, Hofbauer C, Horling F, Allacher P, Wolfsegger M, Oldenburg J, et al.
Blood
. 2012 Dec;
121(6):1039-48.
PMID: 23243272
Neutralizing antibodies against factor VIII (FVIII) remain the major complication in the replacement therapy of hemophilia A patients. To better understand the evolution of these antibodies it is important to...
8.
Bonfig W, Schwarz H
J Pediatr Endocrinol Metab
. 2012 Nov;
25(7-8):645-9.
PMID: 23155688
Background: A typical growth pattern with decreased pubertal growth spurt has been identified in patients with classical congenital adrenal hyperplasia (CAH). Objective: To evaluate the accuracy of final height predictions...
9.
Gupta S, Schwarz H
J Clin Immunol
. 2012 Aug;
33 Suppl 1:S1-3.
PMID: 22878840
No abstract available.
10.
Schiviz A, Wuersch K, Piskernik C, Dietrich B, Hoellriegl W, Rottensteiner H, et al.
Blood
. 2012 Apr;
119(25):6128-35.
PMID: 22529289
Deficiency of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13), a VWF-cleaving protease, is the key factor in the pathogenesis of thrombotic thrombocytopenic purpura (TTP),...